Sarcoma Resection at Expert Centers Associated With Better Outcomes
Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.
|The following article features coverage from the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. Click here to read more of Cancer Therapy Advisor's conference coverage.|
Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers, according to a registry study presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Spain.1
In France, patients with sarcoma have been required to present to a reference sarcoma center since 2010, and patient data and outcomes are collected in a database. NETSARC comprises 26 expert reference sarcoma centers dedicated to improving sarcoma outcomes. The purpose of this study was to evaluate prognostic factors associated with local relapse-free survival (LRFS), relapse-free survival (RFS), and overall survival (OS) by comparing these outcomes between NETSARC centers and nonexpert centers.
The registry included 9594 patients aged 15 or older with nonmetastatic soft tissue or visceral sarcoma diagnosed between 2010 and 2014. Of these patients, 37% and 63% underwent surgical resection at a NETSARC center or another center, respectively. Patients who received care at a NETSARC center had worse prognostic indicators, including age and size, grade, and depth of the tumor, compared with patients who received care at another center.
Surgical resection at a NETSARC center was associated with significantly prolonged median LRFS (60 vs 41 months, respectively) and median RFS (25 vs 21 months, respectively) compared with surgery conducted at another center (log rank P < .001). This benefit was consistent across all qualities of resection (R0 to R2 and Runknown; P < .001).
Surgical care at a NETSARC center was also an independent prognostic factor for LRFS, RFS, and OS according to a Cox analysis (P < .001 for all).
RELATED: Phase 2/3 Trial of Selinexor for Dedifferentiated Liposarcoma
According to the investigators, these data suggest that patients with sarcoma achieve better LRFS and RFS outcomes at NETSARC centers compared with other centers.
Read more of Cancer Therapy Advisor's coverage of the European Society of Medical Oncology (ESMO) 2017 Congress by visiting the conference page.
- Blay J, Stoeckle E, Italiano A, et al. Improved overall and progression free survival after surgery in expert sites for sarcoma patients: a nationwide of FSG-GETO/NETSARC. Presented at: 2017 ESMO Congress; Madrid, Spain: September 8-12, 2017. Abstract 1474O.